We help oncology Pharma and Biotech companies develop next generation medications
From MOA to dose finding, from patient stratification to treatment monitoring and efficacy assessment, contact us today to find out if DiviTum® TKa should be included in your drug development program.
The Biovica CDx Service-for-Pharma business operates as a fee-for-service R&D partner to oncology Pharma, offering the DiviTum® TKa test/assay as a Research Use Only (RUO) collaborative tool for pre-clinical and phase I/II pharma studies during Rx development.
During the later stages of drug development (phase II/III), Biovica offers CDx-co-development, IVD registration and commercialization based on the Biovica biomarker assay.
We offer individualized guidance, planning, execution, analyses, and discussion of results with regards to your study and the inclusion of our biomarker assay, based on our many years of experience with the biomarker assay.”
SVP Business Development